TY - JOUR
T1 - Thromboembolism in Acute Lymphoblastic Leukemia
T2 - Results of nopho all2008 protocol treatment in patients aged 1 to 45 years
AU - Rank, Cecilie Utke
AU - Toft, Nina
AU - Tuckuviene, Ruta
AU - Grell, Kathrine
AU - Nielsen, Ove Juul
AU - Frandsen, Thomas Leth
AU - Marquart, Hanne Vibeke Hansen
AU - Albertsen, Birgitte Klug
AU - Tedgård, Ulf
AU - Hallböök, Helene
AU - Ruud, Ellen
AU - Jarvis, Kirsten Brunsvig
AU - Quist-Paulsen, Petter
AU - Huttunen, Pasi
AU - Wartiovaara-Kautto, Ulla
AU - Jónsson, Ólafur Gísli
AU - Trakymiene, Sonata Saulyte
AU - Griškevičius, Laimonas
AU - Saks, Kadri
AU - Punab, Mari
AU - Schmiegelow, Kjeld
N1 - © 2018 by The American Society of Hematology.
PY - 2018/5/31
Y1 - 2018/5/31
N2 - Thromboembolism frequently occurs during acute lymphoblastic leukemia (ALL) therapy. We prospectively registered thromboembolic events during the treatment of 1772 consecutive Nordic/Baltic patients with ALL aged 1 to 45 years who were treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol (July 2008-April 2017). The 2.5-year cumulative incidence of thromboembolism (N 5 137) was 7.9% (95% confidence interval [CI], 6.6-9.1); it was higher in patients aged at least 10 years (P < .0001). Adjusted hazard ratios (HRas) were associated with greater age (range, 10.0-17.9 years: HRa, 4.9 [95% CI, 3.1-7.8; P < .0001]; 18.0-45.9 years: HRa, 6.06 [95% CI, 3.65-10.1; P < .0001]) and mediastinal mass at ALL diagnosis (HRa, 2.1; 95% CI, 1.0-4.3; P 5 .04). In a multiple absolute risk regression model addressing 3 thromboembolism risk factors, age at least 10 years had the largest absolute risk ratio (RR
age, 4.7 [95% CI, 3.1-7.1]; RR
enlarged lymph nodes, 2.0 [95% CI, 1.2-3.1]; RR
mediastinal mass, 1.6 [95% CI, 1.0-2.6]). Patients aged 18.0 to 45.9 years had an increased hazard of pulmonary embolism (HRa, 11.6; 95% CI, 4.02-33.7; P < .0001), and patients aged 10.0 to 17.9 years had an increased hazard of cerebral sinus venous thrombosis (HRa, 3.3; 95% CI, 1.5-7.3; P 5 .003) compared with children younger than 10.0 years. Asparaginase was truncated in 38/128 patients with thromboembolism, whereas thromboembolism diagnosis was unassociated with increased hazard of relapse (P 5 .6). Five deaths were attributable to thromboembolism, and patients younger than 18.0 years with thromboembolism had increased hazard of dying compared with same-aged patients without thromboembolism (both P £ .01). In conclusion, patients aged at least 10 years could be candidates for preemptive antithrombotic prophylaxis. However, the predictive value of age 10 years or older, enlarged lymph nodes, and mediastinal mass remain to be validated in another cohort.
AB - Thromboembolism frequently occurs during acute lymphoblastic leukemia (ALL) therapy. We prospectively registered thromboembolic events during the treatment of 1772 consecutive Nordic/Baltic patients with ALL aged 1 to 45 years who were treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol (July 2008-April 2017). The 2.5-year cumulative incidence of thromboembolism (N 5 137) was 7.9% (95% confidence interval [CI], 6.6-9.1); it was higher in patients aged at least 10 years (P < .0001). Adjusted hazard ratios (HRas) were associated with greater age (range, 10.0-17.9 years: HRa, 4.9 [95% CI, 3.1-7.8; P < .0001]; 18.0-45.9 years: HRa, 6.06 [95% CI, 3.65-10.1; P < .0001]) and mediastinal mass at ALL diagnosis (HRa, 2.1; 95% CI, 1.0-4.3; P 5 .04). In a multiple absolute risk regression model addressing 3 thromboembolism risk factors, age at least 10 years had the largest absolute risk ratio (RR
age, 4.7 [95% CI, 3.1-7.1]; RR
enlarged lymph nodes, 2.0 [95% CI, 1.2-3.1]; RR
mediastinal mass, 1.6 [95% CI, 1.0-2.6]). Patients aged 18.0 to 45.9 years had an increased hazard of pulmonary embolism (HRa, 11.6; 95% CI, 4.02-33.7; P < .0001), and patients aged 10.0 to 17.9 years had an increased hazard of cerebral sinus venous thrombosis (HRa, 3.3; 95% CI, 1.5-7.3; P 5 .003) compared with children younger than 10.0 years. Asparaginase was truncated in 38/128 patients with thromboembolism, whereas thromboembolism diagnosis was unassociated with increased hazard of relapse (P 5 .6). Five deaths were attributable to thromboembolism, and patients younger than 18.0 years with thromboembolism had increased hazard of dying compared with same-aged patients without thromboembolism (both P £ .01). In conclusion, patients aged at least 10 years could be candidates for preemptive antithrombotic prophylaxis. However, the predictive value of age 10 years or older, enlarged lymph nodes, and mediastinal mass remain to be validated in another cohort.
UR - http://www.scopus.com/inward/record.url?scp=85048188042&partnerID=8YFLogxK
U2 - 10.1182/blood-2018-01-827949
DO - 10.1182/blood-2018-01-827949
M3 - Journal article
C2 - 29661787
SN - 0006-4971
VL - 131
SP - 2475
EP - 2484
JO - Blood
JF - Blood
IS - 22
ER -